Inflammatory bowel diseases(IBD)are chronic inflammatory disorders of the gastrointestinal tract associated with multifactorial conditions such as ulcerative colitis and Crohn’s disease.Although the underlying mechan...Inflammatory bowel diseases(IBD)are chronic inflammatory disorders of the gastrointestinal tract associated with multifactorial conditions such as ulcerative colitis and Crohn’s disease.Although the underlying mechanisms of IBD remain unclear,growing evidence has shown that dysregulated immune system reactions in genetically susceptible individuals contribute to mucosal inflammation.However,conventional treatments have been effective in inducing remission of IBD but not in preventing the relapse of them.In this way,mesenchymal stromal cells(MSC)therapy has been recognized as a promising treatment for IBD due to their immunomodulatory properties,ability to differentiate into several tissues,and homing to inflammatory sites.Even so,literature is conflicted regarding the location and persistence of MSC in the body after transplantation.For this reason,recent studies have focused on the paracrine effect of the biofactors secreted by MSC,especially in relation to the immunomodulatory potential of soluble factors(cytokines,chemokines,and growth factors)and extracellular vehicles that are involved in cell communication and in the transfer of cellular material,such as proteins,lipids,and nucleic acids.Moreover,treatment with interferon-γ,tumor necrosis factor-α,and interleukin-1βcauses MSC to express immunomodulatory molecules that mediate the suppression via cell-contact dependent mechanisms.Taken together,we present an overview of the role of bioactive factors and cell membrane proteins derived from MSC as a cell-free therapy that can improve IBD treatment.展开更多
目的应用分类决策树(classification and regression tree,CART)算法构建胸片鉴别新生儿透明膜病及湿肺病的诊断模型,探讨多种临床及影像因素对肺透明膜病及湿肺病的诊断价值。方法病例为2008年1月～2010年12月间经过临床及影像证实的...目的应用分类决策树(classification and regression tree,CART)算法构建胸片鉴别新生儿透明膜病及湿肺病的诊断模型,探讨多种临床及影像因素对肺透明膜病及湿肺病的诊断价值。方法病例为2008年1月～2010年12月间经过临床及影像证实的新生儿肺透明膜病43例、湿肺病48例。分别提取和上述两种疾病有关的6个临床指标和7个影像学指标作为CART预测新生儿肺透明膜病及湿肺病的变量。用CART建立两者鉴别诊断的分类决策模型,并通过交互验证方法计算该模型的诊断可靠性。同时比较高年资医师与CART诊断结果的一致性。结果建立的CART诊断模型共有九条诊断路径,能够比较可靠区分新生儿肺透明病及湿肺病;模型揭示对区分两者最具价值的X线征象是:支气管气像、孕周、毛玻璃样改变和水平裂的出现。另外,统计分析显示,CART模型和高年资医师对两种疾病诊断的一致性分别是中度一致(湿肺病,Kappa值为0.553)和较高度一致(肺透明膜病,Kappa值为0.628)。结论分类决策树算法可以应用于新生儿的肺透明病及湿肺病的鉴别诊断。展开更多
文摘Inflammatory bowel diseases(IBD)are chronic inflammatory disorders of the gastrointestinal tract associated with multifactorial conditions such as ulcerative colitis and Crohn’s disease.Although the underlying mechanisms of IBD remain unclear,growing evidence has shown that dysregulated immune system reactions in genetically susceptible individuals contribute to mucosal inflammation.However,conventional treatments have been effective in inducing remission of IBD but not in preventing the relapse of them.In this way,mesenchymal stromal cells(MSC)therapy has been recognized as a promising treatment for IBD due to their immunomodulatory properties,ability to differentiate into several tissues,and homing to inflammatory sites.Even so,literature is conflicted regarding the location and persistence of MSC in the body after transplantation.For this reason,recent studies have focused on the paracrine effect of the biofactors secreted by MSC,especially in relation to the immunomodulatory potential of soluble factors(cytokines,chemokines,and growth factors)and extracellular vehicles that are involved in cell communication and in the transfer of cellular material,such as proteins,lipids,and nucleic acids.Moreover,treatment with interferon-γ,tumor necrosis factor-α,and interleukin-1βcauses MSC to express immunomodulatory molecules that mediate the suppression via cell-contact dependent mechanisms.Taken together,we present an overview of the role of bioactive factors and cell membrane proteins derived from MSC as a cell-free therapy that can improve IBD treatment.
文摘目的应用分类决策树(classification and regression tree,CART)算法构建胸片鉴别新生儿透明膜病及湿肺病的诊断模型,探讨多种临床及影像因素对肺透明膜病及湿肺病的诊断价值。方法病例为2008年1月～2010年12月间经过临床及影像证实的新生儿肺透明膜病43例、湿肺病48例。分别提取和上述两种疾病有关的6个临床指标和7个影像学指标作为CART预测新生儿肺透明膜病及湿肺病的变量。用CART建立两者鉴别诊断的分类决策模型,并通过交互验证方法计算该模型的诊断可靠性。同时比较高年资医师与CART诊断结果的一致性。结果建立的CART诊断模型共有九条诊断路径,能够比较可靠区分新生儿肺透明病及湿肺病;模型揭示对区分两者最具价值的X线征象是:支气管气像、孕周、毛玻璃样改变和水平裂的出现。另外,统计分析显示,CART模型和高年资医师对两种疾病诊断的一致性分别是中度一致(湿肺病,Kappa值为0.553)和较高度一致(肺透明膜病,Kappa值为0.628)。结论分类决策树算法可以应用于新生儿的肺透明病及湿肺病的鉴别诊断。
